2024 Marked by Collaboration, Community, Commitment

As 2024 comes to a close, Coalition to Cure Calpain 3 (C3) is energized as we look back on a year marked by collaboration, community, and a continued commitment to drive research toward a cure for individuals living with limb-girdle muscular dystrophy type 2A (LGMD2A/R1), Calpainopathy.

COLLABORATION

We understand that collaboration is critical to accelerate therapies in the LGMD field. Partnering with researchers, clinicians, industry, funding agencies, and patient advocacy groups led to three key initiatives this year.

• Organizing an interactive and productive LGMD2A/R1 Scientific Meeting
• Partnering with the Muscular Dystrophy Association to fund gene therapy research
• Joining the C-PATH LGMD Task Force

COMMUNITY

The C3 team wants to thank each and every patient, family member, and friend who make up the C3 Community. You have demonstrated throughout the year that you are dedicated to doing your part to drive research toward a cure. You championed the cause in 2024 in these three crucial ways:

• Enrolling or completing your annual update in the LGMD2A/Calpainopathy Patient Registry
• Participating in clinical outcome assessment and natural history studies
• Donating online or by check; inviting others to contribute in honor of a special occasion or in memory of a loved one; creating fundraisers; and contributing to surpassing our Giving Tuesday Matching Challenge goal

COMMITMENT TO A CURE

Our founders understand firsthand the physical and emotional toll that living with LGMD2A/R1 takes on patients. That’s why our mission, since our founding in 2010, has been to drive research toward a life-altering treatment or cure for everyone impacted by this rare disease.

We are looking ahead to 2025 with an unwavering commitment and a real sense of optimism as Scientific Directory Dr. Jennifer Levy guides the upcoming round of research projects to accelerate progress and bring hope to the C3 Community.

DONATE NOW TO MAKE A YEAR-END CONTRIBUTION TO C3: TOGETHER, WE ARE OVERCOMING WEAKNESS WITH STRENGTH